Siemens launches ELF test in the U.S. for NASH assessment

2019 08 20 22 16 4501 Liver Anatomy 400

Siemens Healthineers has launched its Enhanced Liver Fibrosis (ELF) blood test in the U.S., designed to assess disease progression in people with nonalcoholic steatohepatitis (NASH). The test will be sold through Labcorp and Quest Diagnostics.

The ELF test is ordered by a physician and generates a numeric score that has been proven to assess prognosis in patients with advanced fibrosis (F3 or F4) due to NASH. The test is now commercially available after receiving de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.

Page 1 of 16
Next Page